New data have shed light on breakthrough infections across all age groups and multiple vaccines 1. The Israel data on restoration of protection vs severe illness with Pfizer booster shots among 4.6 million people medrxiv.org/content/10.110…
2. The New York State data for decline in protection from confirmed infections in all age groups for Pfizer, Moderna and J&J vaccines among 8.8 million people medrxiv.org/content/10.110…
3. Summary of recent reports for decline (from >90%) in vaccine effectiveness vs symptomatic infections for Pfizer, Moderna, and AZ vaccines
4. Most breakthrough hospitalizations occur in people over age 65. The summary of recent studies shows a significant reduction of vaccine effectiveness for this subgroup
5. Nearly all breakthrough deaths occur in people over age 60. The Israel data for people 60+ shows protection from death with Pfizer boosters (14.7-fold, primary analysis) medrxiv.org/content/10.110…
6. Bottom line:
To prevent symptomatic infections, a 3rd shot (booster) will be needed at ~6 months from vaccination in many people.
To prevent hospitalizations and deaths, a booster is necessary for people over age 60.
7. Supporting the last point, preventing deaths
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Covid vaccines are essential and have had a profoundly positive impact.
There's controversy as to whether boosters will be useful for age <60.
New data highlights significantly less protection vs symptomatic infections and, to a lesser extent, hospitalizations /1
Summary of the recent data for vaccine effectiveness vs symptomatic infections. At 2 months, this was well over 90% for mRNA vaccines, but by 4-6+ months has declined to between 44-70%.
All ages.
Data for Pfizer, Moderna, and AZ /2
This could turn out to be one of the most important advances to counter Covid. Molnupiravir, a pill for 5 days (I'll nickname "M-pack") to markedly reduce hospitalization. Await details beyond press release, including safety statnews.com/2021/10/01/mer… by @matthewherper@statnews
Molnupiravir is a broad spectrum anti-viral that achieves "lethal mutagenesis" of #SARSCoV2. Unlike remdesivir, it's a pill, it's not repurposed, had solid data from a Phase 2 trial supporting potency + safety vs Covid nature.com/articles/s4159…@nature The mechanism of action 👇
The fact that the new clinical trial was stopped by the Data and Safety Monitoring Board early because of overwhelming efficacy, deeming it unethical to proceed, would be considered a Eureka moment in the fight against Covid
Why are symptomatic post-vaccination covid infections, without hospitalization (H), important?
—they can be severe, on the brink of H
—they can result in #LongCovid
—they can transmit to others
—they were the primary endpoint of the vaccine clinical trials for efficacy
Inconvenient truth #1
The waning of vaccine effectiveness vs symptomatic infections for both Pfizer and Moderna across all age 20+ groups, presented at @CDCgov Advisory meeting last week cdc.gov/vaccines/acip/…
Inconvenient truth #2
Transmission among fully vaccinated health care workers, with some asymptomatic individuals with higher viral loads than those with symptoms papers.ssrn.com/sol3/papers.cf…
(not common, but it can occur)
The waning of Pfizer and Moderna vaccine protection vs *symptomatic infections* over time in all age groups, slide presented at ACIP @CDCgov meeting by Sara Oliver MD cdc.gov/vaccines/acip/…
(this was the primary endpoint for the pivotal trials to approve these vaccines)
Red=Delta (Green=pre-Delta)
It's still early into the period of waning, w/ frequency of exposures increasing over time.
Recall the UK (and other countries) decision to provide 3rd shots irrespective of vaccine to all age 50+ is at odds with FDA/CDC (Pfizer only, age 65+)
Meanwhile we have left the people who got a J&J vaccine stranded with comparatively very low antibody levels 2-6 weeks after dosing, while we've learned such levels are tied to protection cdc.gov/mmwr/volumes/7…
I think that's now ill-considered.
New reports @NEJM today support higher vaccine effectiveness (VE) of Moderna over Pfizer, with both providing strong level of protection 1. vs Symptomatic infection in health care personnel 96.3 vs 88.8% (see Table for 95% CI, slight overlap) nejm.org/doi/full/10.10…
2. ~6-Month Follow-Up of Moderna pivotal trial nejm.org/doi/full/10.10…
VE 98.2% vs severe disease (here VE = vaccine efficacy, with a placebo control)
Difference between protection, VE for symptomatic infections during extended follow-up of Pfizer and Moderna
Pfizer data nejm.org/doi/full/10.10…
New large dataset of US Medicare (age 65+) population subgroup: 2.7 million Pfizer; 2.9 million Moderna vaccinated, w/ ~30,000 breakthrough hospitalizations, via claims 🧵main findings @Humetrixhumetrix.com/powerpoint-vac…
1. Definite waning of protection vs hospitalization for those 5-6 months out from vaccination (odd ratio 2.5X at 6 months)
2. No significant difference of waning for Pfizer vs Moderna for protection from breakthrough infections